KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to -$200.0 million.

  • Moderna's Net Income towards Common Stockholders fell 163846.15% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 4010.79%. This contributed to the annual value of -$3.6 billion for FY2024, which is 2445.91% up from last year.
  • Latest data reveals that Moderna reported Net Income towards Common Stockholders of -$200.0 million as of Q3 2025, which was down 163846.15% from -$825.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Net Income towards Common Stockholders peaked at $4.9 billion during Q4 2021, and registered a low of -$3.6 billion during Q3 2023.
  • Over the past 5 years, Moderna's median Net Income towards Common Stockholders value was $79.0 million (recorded in 2023), while the average stood at $541.7 million.
  • As far as peak fluctuations go, Moderna's Net Income towards Common Stockholders skyrocketed by 247606.84% in 2021, and later plummeted by 163846.15% in 2025.
  • Moderna's Net Income towards Common Stockholders (Quarter) stood at $4.9 billion in 2021, then tumbled by 69.91% to $1.5 billion in 2022, then plummeted by 85.19% to $217.0 million in 2023, then plummeted by 616.13% to -$1.1 billion in 2024, then soared by 82.14% to -$200.0 million in 2025.
  • Its last three reported values are -$200.0 million in Q3 2025, -$825.0 million for Q2 2025, and -$971.0 million during Q1 2025.